262 episodes
- What's trending in the world of pathogens? In this introductory episode of our new mini-series, we explore how data from routine diagnostic testing can help us better understand pathogen activity.
Learn how testing results from participating healthcare facilities can provide insights into which pathogens are being detected and how those patterns change over time.
We'll also discuss what you can expect from this series, beginning with respiratory pathogens and later exploring gastrointestinal pathogens.
Sponsored by bioMérieux. Insights provided by BIOFIRE® FIREWORKS™ Trends, powered by syndromic testing.
Stay connected with Let's Talk Micro:
Website: letstalkmicro.com
Questions or feedback? Email me at letstalkmicro@outlook.com
Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8
Support the podcast:
Venmo
Buy me a Ko-fi - It's time to revisit acid-fast bacilli (AFB)!
What is acid-fastness? What stains are used to detect AFB, and how are AFB cultures processed?
In this episode of Let's Talk Micro, Luis revisits a conversation with Dr. Filipe Muniz (Cerqueira) about the fundamentals of AFB. They discuss acid-fast staining, specimen processing, culture media, and the Runyon groups. Dr. Muniz also discusses nontuberculous mycobacteria (NTM), including examples of clinically relevant organisms and their characteristics.
Whether you're new to clinical microbiology or looking for a refresher, tune in to this episode from the archives!
Note: This episode was originally released on January 30TH 2025. At the time of recording, Dr. Muniz was serving as a clinical microbiology laboratory director at the University of Alabama at Birmingham (UAB). He is no longer in that role and is currently a medical student at UAB.
Stay connected with Let's Talk Micro:
Website: letstalkmicro.com
Questions or feedback? Email me at letstalkmicro@outlook.com
Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8
Support the podcast:
Venmo
Buy me a Ko-fi - In 2026, a multistate outbreak of cyclosporiasis led to a significant increase in testing across clinical and public health laboratories. How did laboratories recognize the increase in cases? What diagnostic approaches were used, and how did laboratory data contribute to the outbreak investigation?
In this episode of Let's Talk Micro, Luis is joined by Dr. Anisha Misra from Cleveland Clinic, Dr. Marie-Claire Rowlinson from bioMérieux, and Dr. Duane Newton from the Michigan Department of Health and Human Services to discuss the laboratory response to the 2026 Cyclospora outbreak.
The conversation explores diagnostic methods for Cyclospora cayetanensis, the challenges of managing increased testing volumes, and the use of diagnostic data to identify emerging trends. The guests also discuss the role of molecular testing and sequencing in public health investigations, the importance of collaboration between clinical laboratories, industry, and public health agencies, and lessons learned that may help laboratories prepare for future outbreaks.
Join us for a discussion about the critical role of clinical microbiology laboratories in outbreak detection, investigation, and response.
Guests
Anisha Misra, PhD — Cleveland Clinic
Marie-Claire Rowlinson, PhD — bioMérieux
Duane Newton, PhD — Michigan Department of Health and Human Services
Resources
CDC – Cyclosporiasis: https://www.cdc.gov/cyclosporiasis/
CDC DPDx – Cyclosporiasis: https://www.cdc.gov/dpdx/cyclosporiasis/
FDA – Cyclospora: https://www.fda.gov/food/foodborne-pathogens/cyclospora
Stay connected with Let's Talk Micro:
Website: letstalkmicro.com
Questions or feedback? Email me at letstalkmicro@outlook.com
Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8
Support the podcast:
Venmo
Buy me a Ko-fi - Metallo-β-lactamases (MBLs) have become an increasingly important topic in clinical microbiology and infectious diseases. While these enzymes were once encountered relatively infrequently in the United States, their epidemiology is changing, with NDM-producing organisms becoming more common. What makes metallo-β-lactamases different from other carbapenemases? Why are infections caused by MBL-producing organisms particularly challenging to treat? And what new treatment options are becoming available?
In this episode of Let's Talk Micro, Luis is joined by Dr. Ryan Shields and Dr. Emily Heil to discuss metallo-β-lactamases and their growing clinical significance. They explore the differences between serine β-lactamases and MBLs, review important enzymes such as NDM, VIM, and IMP, and discuss the challenges associated with treating infections caused by MBL-producing organisms. The conversation also covers emerging treatment options, including aztreonam-avibactam and cefepime-zidebactam, and highlights the importance of identifying specific carbapenemases to guide antimicrobial therapy.
Join us for a discussion on the evolving landscape of metallo-β-lactamases and the essential role of the clinical microbiology laboratory in patient care.
Guests:
Ryan Shields, PharmD — University of Pittsburgh
Emily Heil, PharmD — University of Maryland School of Pharmacy and University of Maryland Medical Center
Additional Reading:
McCreary EK, Heil EL, Aitken SL, et al. The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens. JAC-Antimicrobial Resistance. 2026;8(5).
https://pubmed.ncbi.nlm.nih.gov/42876900/
Stay connected with Let's Talk Micro:
Website: letstalkmicro.com
Questions or feedback? Email me at letstalkmicro@outlook.com
Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8
Support the podcast:
Venmo
Buy me a Ko-fi - When you open CLSI M100, what are you usually looking for? Susceptibility breakpoints? But did you know there's much more information available beyond susceptible, intermediate, and resistant interpretations?
In this episode of Micro Minutes, we explore useful information found throughout CLSI M100, including its tables, comments, and appendices. From intrinsic resistance and predicting susceptibility to other antimicrobials to understanding why certain agents should not be reported as susceptible, we highlight practical examples that can help clinical microbiology professionals interpret antimicrobial susceptibility results.
Whether you're a student or an experienced laboratory professional, join us as we take a closer look at CLSI M100 and discover what's beyond S, I, and R.
Stay connected with Let's Talk Micro:
Website: letstalkmicro.com
Questions or feedback? Email me at letstalkmicro@outlook.com
Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8
Support the podcast:
Venmo
Buy me a Ko-fi
More Life Sciences podcasts
Trending Life Sciences podcasts
About Let's Talk Micro
Clinical microbiology explained in simple terms, suitable for students and microbiologists alike. We discuss organisms, reactions, infectious diseases, and more. Hosted by Luis Plaza, a Medical Laboratory Scientist and microbiologist, who also shares his experiences in the field.
Podcast websiteListen to Let's Talk Micro, Ask the Naked Scientists and many other podcasts from around the world with the radio.net app

Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features













